Sino Biopharmaceutical (HK:1177) has released an update.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Sino Biopharmaceutical has announced a significant breakthrough with its new combination treatment for advanced hepatocellular carcinoma, showcasing promising results in a Phase III clinical trial. The treatment, combining Anlotinib Hydrochloride Capsule with Penpulimab injection, demonstrated improved progression-free survival and overall survival rates compared to existing treatments. This development could provide a crucial new option for liver cancer patients, potentially enhancing the company’s market position and innovative pipeline.
For further insights into HK:1177 stock, check out TipRanks’ Stock Analysis page.
